Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com THOUSAND OAKS, Calif. (Aug. 6, 2024) - Amgen (NASDAQ:AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: • Fo ...

Amgen Inc. AMGN is expected to release earnings results for its second quarter, after the closing bell on Tuesday, Aug. 6.Analysts expect the Thousand Oaks, California-based company to report quarterly earnings at $5.01 per share, up slightly from $5.00 per share in the year-ago quarter. Amgen is projected to report quarterly revenue of $8.33 billion, compared to $6.99 billion a year earlier, according to data from Benzinga Pro.On Aug. 2, Amgen declared a $2.25 per share dividend for the third quarter of 20 ...

THOUSAND OAKS, Calif., Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024. The dividend will be paid on September 6, 2024, to all stockholders of record as of the close of business on August 16, 2024.About Amgen   Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, A ...

Investing in biotech stocks is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their investigational therapies fail to make it to market.The pandemic focused a lot of attention on the sector. The SDPR S&P Biotech ETF (NYSEARCA:XBI) soared 49% in 2020, outpacing the S&P 500 and the Nasdaq 100. But the exchange-traded fund has faced a more difficult road since. The ETF is down 30% as investor attentio ...

Amgen (AMGN) closed the latest trading day at $335.53, indicating a +0.92% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 1.37%. Meanwhile, the Dow lost 1.21%, and the Nasdaq, a tech-heavy index, lost 2.3%.Coming into today, shares of the world's largest biotech drugmaker had gained 7.46% in the past month. In that same time, the Medical sector gained 0.74%, while the S&P 500 gained 1.11%.The investment community will be closely monitoring the perfor ...

In its upcoming report, Amgen (AMGN) is predicted by Wall Street analysts to post quarterly earnings of $4.92 per share, reflecting a decline of 1.6% compared to the same period last year. Revenues are forecasted to be $8.3 billion, representing a year-over-year increase of 18.9%.Over the last 30 days, there has been an upward revision of 0.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecas ...

In the bustling world of biotechnology, innovation remains the cornerstone of growth. Some biotech stocks, known for their groundbreaking research and rapid adaptation to health challenges, are particularly well-positioned to do well in the future.The global biotechnology market, valued at $1.54 trillion in 2023, is expected to soar to $5.68 trillion by 2033. This growth is expected to be fueled by various factors, including strong government support, advancements in regulatory frameworks, and the rising po ...

The market expects Amgen (AMGN) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Augus ...

Bill Oxford The market has seen a huge sector rotation recently out of Big Tech and Magnificent Seven stocks into the Dow components, and small and mid-cap stocks. The SPDR® S&P Biotech ETF (XBI) has been the beneficiary of this move. Over the last month, this small/mid-cap biotech ETF has spurted ahead by some 10% while money has come out of the likes of Alphabet Inc. (GOOG), Nvidia Corporation (NVDA) and Microsoft (MSFT). Seeking Alpha If the rally in small and mid-cap biotech equities continues, here ...

Amgen (AMGN) ended the recent trading session at $334.85, demonstrating a +0.16% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 1.11% for the day. At the same time, the Dow added 1.64%, and the tech-heavy Nasdaq gained 1.03%.Prior to today's trading, shares of the world's largest biotech drugmaker had gained 6.57% over the past month. This has outpaced the Medical sector's loss of 0.54% and the S&P 500's loss of 1.16% in that time.Market partici ...